In the treatment of unresectable
or metastatic melanoma

Maybe it's time to look
for another driver

NRAS mutations may be affecting more of your patients than you think

Learn More

NRAS Matters sheds light on NRAS mutations, an underrecognized molecular driver in unresectable or metastatic melanoma. Sponsored by Array BioPharma, NRAS Matters delivers current perspectives and information on NRAS mutations, encouraging oncologists to test for NRAS mutations when evaluating patients and helping to enhance the clinical picture that informs treatment decisions.

NRAS Mutations

Learn More


Learn More

Mutation Testing

Learn More


Learn More

Array BioPharma

is dedicated to research aimed at addressing the unmet needs of patients and physicians facing the challenges of melanoma.

You are now leaving

The website you are linking to is neither owned nor controlled by Array BioPharma. Array BioPharma is not responsible for the content or services on the site.